TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03342209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy
Description: A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.
Study: NCT03783312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: 800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Study: NCT03437980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
Study: NCT04022265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
Study: NCT02271763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: subjects' neck will be scanned using ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: subjects' neck will be scanned using ultrasound
Study: NCT03641690

Intervention type: OTHER
Intervention: Empirical antimicrobial therapy
Description: All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
Study: NCT02337816

Intervention type: PROCEDURE
Intervention: laparoscopic surgery, obtainment of biological samples

Intervention type: PROCEDURE
Intervention: laparoscopic surgery, obtainment of biological samples
Study: NCT02564094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
Study: NCT03576807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20 CAR-T cells
Description: A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
Study: NCT01503229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT04281966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ability School Engagement Program Conference
Description: The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work.
Study: NCT01632007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02613910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine (cetirizine or equivalent)
Description: Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
Study: NCT04296331

Intervention type: DIAGNOSTIC_TEST
Intervention: POC
Description: DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry

Intervention type: DIAGNOSTIC_TEST
Intervention: Ag/Ab
Description: The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.

Intervention type: DIAGNOSTIC_TEST
Intervention: POC + Ag/Ab
Description: As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
Study: NCT01150149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No face touch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical face mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical face mask + no face touch
Study: NCT04369443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large volume Acute Normovolemic Hemodilution
Description: Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
Study: NCT03776435

Intervention type: RADIATION
Intervention: Abdomen CT
Description: Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.

Intervention type: RADIATION
Intervention: Abdomen CT
Description: Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
Study: NCT00612573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 0.6 mg/kg/day
Description: doxycycline 40 mg/day, oral, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 1.2 mg/kg/day
Description: doxycycline 80 mg/day, 12 weeks
Study: NCT02112864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2.5 mL normal saline
Study: NCT01964638

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Targeted Biopsy
Study: NCT00612573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 2.4 mg/kg/day
Description: doxycycline 160 mg/day, 12 weeks
Study: NCT02864160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
Study: NCT02788708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00612573

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 12 weeks
Study: NCT02864160

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
Study: NCT03818451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Co-ultraPEALut (Glialia)
Description: Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
Study: NCT04374045

Intervention type: OTHER
Intervention: ECG-Holter
Description: Patient will have a ECG-Holter recording during all their hospitalization.
Study: NCT00745043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bronchodilator response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bronchodilator response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bronchodilator response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bronchodilator response
Study: NCT01079494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmaceutical care services
Description: Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
Study: NCT04674657

Intervention type: DRUG
Intervention: blood drug concentration
Description: blood drug concentration

Intervention type: DRUG
Intervention: blood drug concentration
Description: blood drug concentration
Study: NCT01771250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Daily doses administered SC.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Daily doses administered SC.
Study: NCT02058563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix®
Description: 1 dose administered as a subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Description: 1 dose administered subcutaneously.
Study: NCT04280731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented quinoa
Description: Quinoa drink fermented with lactic acid bacteria isolated from food
Study: NCT04673760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized palliative home care
Description: Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team.
Study: NCT00606463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Ablation (Gen2 Cardiac Ablation System)
Description: Ablation of isthmus-dependent atrial flutter
Study: NCT02534246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound biopsy needle Echo Tip ProCore
Description: Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound biopsy needle SharkCore
Study: NCT01921764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home physical exercise
Study: NCT02415270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Cigarettes
Description: Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced ROS/RNS
Description: Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
Study: NCT01647776

Intervention type: OTHER
Intervention: Stool DNA Test
Description: Stool DNA test is done prior to the colonoscopy.

Intervention type: OTHER
Intervention: Stool DNA Test
Description: Stool DNA test is done prior to the colonoscopy.

Intervention type: PROCEDURE
Intervention: biopsies of rectal and colon mucosa
Description: During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.

Intervention type: PROCEDURE
Intervention: biopsies of rectal and colon mucosa
Description: During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.

Intervention type: OTHER
Intervention: Questionnaires
Description: A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
Study: NCT03965416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Coat
Description: We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without White Coat
Description: We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
Study: NCT01647776

Intervention type: OTHER
Intervention: Questionnaires
Description: A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
Study: NCT00461084

Intervention type: DRUG
Intervention: BIAXIN (CLARITHROMYCIN)
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.

Intervention type: DRUG
Intervention: Biaxin (clarithromycin)
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
Study: NCT02982057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the ABSORB:bioresorbable vascular scaffold

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: O.M.T
Study: NCT02788708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02213094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg
Description: Nicotinamide 500 mg taken by mouth each morning
Study: NCT04039217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
Study: NCT03364309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02213094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide 1000 mg
Description: Nicotinamide 1000 mg taken by mouth each morning
Study: NCT00711009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r)
Description: LPV/r 400/100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Description: LPV/r 400/100 mg BID
Study: NCT01371552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
Study: NCT00711009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Description: FTC/TDF 200/300 mg QD
Study: NCT01371552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon II 3 contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3 contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3 contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
Study: NCT00711009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir (RAL)
Description: RAL 400 mg BID
Study: NCT01270139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of nanoparticles
Description: 60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of iron-bearing nanoparticles
Description: 60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
Study: NCT00032357

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ferritin reduction to 25 ng/ml by phlebotomy